Diab MR (Gliclazide MR) is commonly used for the long-term management of Type 2 Diabetes Mellitus in adults. Its therapeutic scope focuses on addressing the core symptomatic and clinical patterns of uncontrolled blood sugar. The product is relevant in situations where patients' blood glucose levels are not sufficiently controlled by dietary measures, physical exercise, and weight loss alone.

---

The medication is applied in addressing elevated blood sugar levels, which are symptoms related to systemic imbalance in Type 2 Diabetes. It is primarily used to manage the pathological cluster of Persistent Hyperglycemia, including high Fasting Plasma Glucose and Postprandial Glucose readings, as well as improving Suboptimal Long-Term Glycemic Control (HbA1c). It is relevant for easing Persistent Hyperglycemia and supports sustained blood glucose level lowering.

“The use may provide supportive relief and may help patients cope more steadily with the metabolic challenges of their condition.”

This medication is relevant in clinical settings where patients require additional symptomatic support due to insufficient control through lifestyle measures. By supporting improved control, it plays a role in managing the overall disease burden associated with chronic high blood sugar.

Quick Fact: Relief for Hyperglycemia	Description
Main Target	Elevated blood sugar (Persistent Hyperglycemia)
Primary Benefit	Supports Sustained Blood Glucose Level Lowering
Use Context	Adults with T2DM refractory to diet and exercise

Eligibility Scope

Diab MR (Gliclazide MR) is officially approved for Adults with Type 2 Diabetes Mellitus. The same regimen may be prescribed for older adults (ge 65 years). Use is permitted in patients with Mild to Moderate Renal Insufficiency with careful monitoring, as defined in regulatory documents.

Populations for Whom Use is Contraindicated

Use is strictly Contraindicated in Type 1 Diabetes Mellitus or during acute states such as Diabetic Ketoacidosis or diabetic coma. The medicine must not be used in cases of Severe Hepatic Insufficiency or Severe Renal Insufficiency. It is also Contraindicated if there is a known hypersensitivity to Gliclazide, other sulfonylureas, or sulfonamides, or during concurrent treatment with Miconazole.

Age and Life Stage Rules

Diab MR is Contraindicated during Pregnancy and Lactation (breastfeeding). Safety and effectiveness have not been established in the pediatric population (children and adolescents under 18 years), and therefore, use is not recommended in this age group.

Eligibility-Related Restrictions

Use is prohibited during acute Stress Conditions, such as serious infection, trauma, or surgery. Caution is advised for patients with G6PD-Deficiency and for those with certain rare hereditary problems like lactose intolerance.

Interactions with other medicines and products

The official regulatory profile for Diab MR (Gliclazide Modified Release) documents interaction patterns primarily focused on changes to the blood glucose-lowering effect and alterations in plasma concentration.

Documented Interaction Classifications

Classification	Entity/Official Description
Contraindicated Combination	Miconazole (systemic route or oromucosal gel). Prohibited due to significantly increased hypoglycemic effect, with potential for coma.
Combination Not Recommended	Alcohol (increases the hypoglycemic reaction by inhibiting compensatory mechanisms).
Combination Not Recommended	St. John’s Wort (Hypericum perforatum), which is documented to potentially reduce Gliclazide exposure.

---

Pharmacodynamic and Exposure Interactions

Interactions that potentiate the blood glucose lowering effect, increasing the risk of hypoglycemia, include other Antidiabetic Agents, beta-blockers, ACE Inhibitors, Fluconazole, and certain NSAIDs (e.g., aspirin). Conversely, substances like Glucocorticoids or Danazol may decrease the drug’s primary effect. Phenylbutazone increases Gliclazide's effect via a pharmacokinetic mechanism, notably through displacement from plasma protein binding and/or reduced elimination. When switching from a prolonged half-life sulfonylurea, a treatment-free period of a few days may be necessary to avoid an additive effect. Regulatory labeling also notes that the risk of a prolonged hypoglycemic episode due to altered pharmacokinetics is a consideration in patients with Severe Hepatic or Renal Insufficiency.

The pharmacological mechanism of Diab MR relies entirely on Gliclazide, a compound classified as an insulin secretagogue. Its mechanism is defined by a highly specific interaction at the cellular level, leading to systemic physiological changes.

---

Direct Activation of Pancreatic Insulin Secretion

The primary mechanism involves targeting the ATP-sensitive Potassium ( K ATP) ion channels on the pancreatic beta-cells via the specific Sulfonylurea Receptor 1 ( SUR1) subunit. Binding of Gliclazide to SUR1 causes the K ATP channel to close, which triggers a molecular cascade of cell membrane depolarization, calcium influx ( Ca^2+), and the ultimate release of pre-formed insulin . This action directly affects the regulation of systemic glucose concentration by increasing circulating insulin.

---

Vascular and Antioxidant Pathway Modulation

Beyond its principal effect, Gliclazide demonstrates mechanistic actions that influence other physiological systems. Its unique chemical structure is associated with antioxidant properties (free-radical scavenging) and the modulation of vascular hemostasis. This secondary mechanism involves the modulation of platelet function, specifically inhibiting platelet adhesion and aggregation.

How to use Diab MR — official administration guidelines

The use of Diab MR, which contains the active substance Gliclazide in a Modified Release (MR) tablet form, is governed by specific administration rules. The medication is designated for oral administration, with the regimen designed around a single daily dose.

The official dosing protocol specifies an initial dose of 30 mg once per day. The maintenance dosage typically falls within the range of 30 mg to 120 mg per day, with 120 mg established as the maximum recommended daily dose. Dose adjustments are generally performed in progressive steps, with a period of at least one month between increments to assess the metabolic response.

---

Administration Specifics and Procedural Constraints

Feature	Official Instruction
Timing in relation to meals	The tablet must be taken as a single daily dose with breakfast.
Preparation requirement	The Modified Release tablet must be swallowed whole with water and must not be chewed or crushed to protect the drug's release characteristics.
Population instruction	The standard regimen is applied to older adults and those with mild-to-moderate renal impairment, requiring careful monitoring during use.
Missed-dose rule	If a dose is forgotten, the amount taken the subsequent day must not be increased to compensate.

This structured administration protocol is explicitly contingent on the patient maintaining a regular food intake, particularly breakfast, to support the proper absorption and action of the medication.

Diab MR: Recent Clinical Evidence

---

Research regarding Diab MR (gliclazide modified release) has focused on its use in adults with type 2 diabetes mellitus (T2DM), both as a single therapy and in combination with other agents, such as metformin.

Glycemic Control and Efficacy

Studies have consistently explored the drug's effect on glycated hemoglobin (HbA1c), which reflects long-term blood sugar control. In large-scale, real-world observational trials, the use of Diab MR was associated with a statistically significant reduction in mean HbA1c levels from baseline over six months.

• Observed HbA1c Change: In certain patient cohorts, an absolute reduction in HbA1c of approximately 1.7% to 1.8% was observed after six months of treatment, with improvements noted across various baseline HbA1c levels and body mass index (BMI) classifications.
• Comparative Studies: Research has demonstrated that Diab MR, when taken once daily, showed similar effectiveness in controlling HbA1c levels compared to the immediate-release formulation (gliclazide) taken in divided doses.

Safety Profile and Secondary Findings

Clinical research has also monitored the drug's safety and tolerability profile, focusing particularly on the risk of hypoglycemia.

Outcome Category	Study Finding	Notes
Hypoglycemia	Low incidence of severe hypoglycemic events reported.	Incidence was observed to be particularly low in the elderly.
Body Weight	Weight neutrality or mild weight loss often noted.	Patients with a higher baseline BMI (e.g., ge 25.0, kg/m^2) often registered a modest weight decrease.
Cardiovascular Risk	Multiple studies suggest no increased risk of cardiovascular events or mortality.	Diab MR is often associated with a lower risk of mortality compared to some older sulfonylureas.

These findings suggest that the modified-release formulation provides durable glycemic control over 24 hours while maintaining a low reported incidence of severe hypoglycemia, which is an important factor in diabetes management.

Key Studies & References

1. Gliclazide modified release and cardiovascular risk in type 2 diabetes: a meta-analysis of randomized controlled trials.
2. NICE Guideline NG28: Type 2 diabetes in adults: management.

Common questions about Diab MR (FAQ)

---

Q: Do I need to change my diet while using Diab MR?

Official information indicates the importance of following dietary advice and maintaining a regular food intake while using this medication. This includes taking Diab MR with breakfast. It is noted that skipping meals or having irregular mealtimes can increase the potential for low blood sugar (hypoglycemia).

Q: Can Diab MR be taken with other diabetes medications?

According to official documents, Diab MR may be used alongside other antidiabetic medicines, such as biguanides (like metformin) or insulin. This approach is sometimes necessary when one medicine alone does not fully control blood sugar. Combination therapy is typically initiated under close medical supervision.

Q: Is Diab MR the same as metformin?

Diab MR contains Gliclazide, which is classified as a sulfonylurea. This type of medicine works by prompting the pancreas to release more insulin. Metformin belongs to a different class of antidiabetic agents called biguanides, meaning the two medicines have distinct mechanisms and are not the same drug.

Q: What kind of monitoring is usually required while on Diab MR?

Regulatory documents state that monitoring is based on the patient's metabolic response to the medicine. This assessment typically involves regular measurement of blood glucose and glycated hemoglobin ( HbA1 c), a measure of long-term blood sugar control. Self-monitoring of blood sugar levels may also be beneficial as part of management.

Q: Is it safe to drive while using Diab MR?

Because Diab MR can cause hypoglycemia (low blood sugar), there is a possibility of experiencing dizziness or drowsiness. Official safety information cautions against driving or operating machinery until patients are familiar with how the medication affects them. This is a general regulatory caution related to the risk of lowered blood sugar.

Q: Does Diab MR change how other oral medications are absorbed?

Official product information notes that food intake does not affect the absorption of Diab MR. However, regulatory documents describe interactions with other medicines, where Gliclazide can affect the concentration of another medicine in the blood by interacting with proteins or affecting metabolism.

Q: How quickly can I expect to see an effect from Diab MR?

Studies show the Modified Release formulation allows the medicine's concentration in the blood to increase steadily, reaching a consistent level between six and twelve hours after a dose. Consistent drug concentration is maintained over 24 hours, and steady state levels are generally achieved after the second day of use.

Q: Are there any specific foods to avoid while on Diab MR?

There are no specific individual foods listed for avoidance in the official product information. However, due to the way this medicine works, regulatory documents emphasize the need to avoid periods of fasting or consuming foods that are low in carbohydrate. This practice is essential for maintaining regular carbohydrate intake and managing the risk of low blood sugar.

Q: What should I do if I notice a change in my health after starting Diab MR?

Official patient information advises that if unusual symptoms or a change in health is noticed after starting this medicine, regulatory information suggests contacting a doctor or healthcare professional. Regulatory information also emphasizes communicating the use of this medicine to any treating doctor, dentist, or pharmacist.

Q: Is Diab MR available in different strengths?

Yes, the medication is marketed as Modified Release tablets that are available in different strengths. These commonly include a 30 mg tablet and a 60 mg tablet.

Q: Are there generic versions of Diab MR?

Studies and official information indicate that Gliclazide Modified Release is available both under its original brand name and as several generic-titled versions. Regulatory records for the active substance show it is marketed under various names in different countries.

Q: Are there long-term safety studies for Diab MR?

Research on Diab MR includes long-term clinical studies to assess its sustained safety and effectiveness over time. Evidence for Gliclazide Modified Release covers periods of up to 24 months, in addition to ongoing Phase 4 post-marketing studies.

Q: Why do doctors prescribe Diab MR over other options?

Studies examining the drug's safety profile have noted its pattern of insulin release may be associated with a lower incidence of hypoglycemia and weight gain. Furthermore, the drug possesses antioxidant properties and unique effects beyond the pancreas.

Q: Is Diab MR considered a new or old drug?

Gliclazide is classified as a second-generation sulfonylurea. While the original chemical compound has been in use since the 1970s, the Modified Release (MR) tablet is a newer formulation designed for convenient once-daily dosing and sustained action.

Q: Why is Diab MR sometimes used with insulin?

Official information confirms that Diab MR may be used in combination with insulin therapy, such as basal insulin. This combination is typically introduced when a patient's blood sugar levels are not fully controlled by Diab MR alone, and combination use is initiated with and requires medical supervision.

Q: Is it necessary to have certain tests before starting Diab MR?

While the requirement for specific pre-treatment tests is not explicitly stated in all documents, the dose is typically adjusted based on the patient's metabolic response. This assessment requires measuring parameters like blood glucose and HbA1 c.

Q: Does Diab MR have a risk of addiction or dependence?

Regulatory documents contain statements indicating that the medicine does not carry a risk of addiction or dependence. There is no reported risk of addiction or dependence associated with its use.

How to Store and Dispose of Diab MR (Gliclazide Modified-Release)

Storage Requirements

Diab MR tablets must be stored according to official regulatory labeling to ensure product stability. The medicine must generally be stored in a dry place below 30 C and protected from excessive heat and moisture. It is mandatory to keep the tablets in the original pack or blister strip until they are used. This requirement safeguards the modified-release formulation. As a universal safety rule, Diab MR must be kept out of the sight and reach of children.

Disposal Instructions

Expired or unused Diab MR must not be thrown away via household waste or wastewater, as mandated by pharmaceutical waste regulations. To ensure environmental protection, the official instruction is to ask a pharmacist how to dispose of any medicines that are no longer needed.